Lv2
168 积分 2026-01-12 加入
Relapse rate following withdrawal of vedolizumab and ustekinumab in patients with inflammatory bowel disease - a multicenter retrospective controlled study. The VEDUST-EXIT Study
17小时前
待确认
Discontinuation of Infliximab in Patients With Ulcerative Colitis Is Associated With Increased Risk of Relapse: A Multinational Retrospective Cohort Study
17小时前
待确认
Anti-TNF withdrawal or long-term treatment in ulcerative colitis (BIOSTOP): a multicentre open label, randomized controlled trial
17小时前
待确认
Discontinuation of infliximab in patients with ulcerative colitis in remission (HAYABUSA): a multicentre, open-label, randomised controlled trial
17小时前
待确认
Corticosteroids for Immune-Related Adverse Events and Checkpoint Inhibitor Efficacy: Analysis of Six Clinical Trials
24天前
已完结
COMPARATIVE REAL-WORLD EFFECTIVENESS OF BIOLOGIC THERAPIES FOR PREVENTING POSTOPERATIVE ENDOSCOPIC RECURRENCE OF CROHN’S DISEASE
24天前
已完结
Roles of the gut microbiota in immune-related adverse events: mechanisms and therapeutic intervention
26天前
已完结
Microbiota and immune-related adverse events in cancer immunotherapy
26天前
已完结
Management of pediatric Crohn’s disease: an ECCO-ESPGHAN guideline update
1个月前
已完结
Genomic diagnosis and care co-ordination for monogenic inflammatory bowel disease in children and adults: consensus guideline on behalf of the British Society of Gastroenterology and British Society of Paediatric Gastroenterology, Hepatology and Nutrition
1个月前
已完结
皖公网安备34019202002308
